Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Aaron T. Gerds, Jingbo Yu, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn Scherber & Shreekant Parasuraman. (2023) Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs. Journal of Medical Economics 26:1, pages 843-849.
Read now
Read now
Josep Darbà & Alicia Marsà. (2022) Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis. Expert Review of Pharmacoeconomics & Outcomes Research 22:6, pages 965-970.
Read now
Read now
Dayu Shi, Hongxia Shi, Xiaoli Liu, Minghui Duan, Junling Zhuang, Xin Du, Ling Qin, Wuhan Hui, Rong Liang, Meifang Wang, Ye Chen, Dongyun Li, Wei Yang, Gusheng Tang, Weihua Zhang, Xia Kuang, Wei Su, Yanqiu Han, Limei Chen, Jihong Xu, Zhuogang Liu, Jian Huang, Chunting Zhao, Hongyan Tong, Jianda Hu, Chunyan Chen, Xiequn Chen, Zhijian Xiao & Qian Jiang. (2021) Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms. Leukemia & Lymphoma 62:11, pages 2703-2715.
Read now
Read now
Aniket Bankar, Haoyu Zhao, Javaid Iqbal, Ruth Coxford, Matthew C. Cheung, Lee Mozessohn, Craig C. Earle & Vikas Gupta. (2020) Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leukemia & Lymphoma 61:8, pages 1908-1919.
Read now
Read now
Björn Vandewalle, Valeska Andreozzi, João Almeida & Jorge Félix. (2016) Pharmacoeconomics of ruxolitinib therapy in patients with myelofibrosis. Journal of Medical Economics 19:4, pages 424-431.
Read now
Read now
Francis Vekeman, Wendy Y. Cheng, Medha Sasane, Lynn Huynh, Mei Sheng Duh, Carole Paley & Ruben A. Mesa. (2015) Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy. Leukemia & Lymphoma 56:10, pages 2803-2811.
Read now
Read now
Articles from other publishers (17)
Sarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjærsgaard, Anna Stenling, Bianka Darvalics, Björn Paulsson, Christen Lykkegaard Andersen, Christian Fynbo Christiansen, Jesper Stentoft, Jørn Starklint, Marianne Tang Severinsen, Mette Borg Clausen, Morten Hagemann Hilsøe, Hans Carl Hasselbalch, Henrik Frederiksen, Ellen Margrethe Mikkelsen & Marie Bak. (2022) Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study. European Journal of Haematology 109:5, pages 526-541.
Crossref
Crossref
Jill Brennan-Cook & Allen Cadavero. (2022) Professional Case Management in Outpatient Settings for Patients With Myeloproliferative Neoplasms. Professional Case Management 27:6, pages 271-276.
Crossref
Crossref
Alanna Barrios-Ruiz, Daniel Davila-Gonzalez, Eric Fountain, Lee Cheng, Srdan Verstovsek & Cristhiam M. Rojas-Hernandez. (2022) Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. Scientific Reports 12:1.
Crossref
Crossref
Ronda Copher, Arianna Kee & Aaron Gerds. (2022) Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States. The Oncologist 27:3, pages 228-235.
Crossref
Crossref
Divya R Gavini, Dhairya J Salvi, Prutha H Shah, Davuluri Uma, Jun Hee Lee & Pousette Hamid. (2021) Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review. Cureus.
Crossref
Crossref
Mark B. Ulanja, Bryce D. Beutler, Daniel Antwi-Amoabeng, Paschal A. Apanga, Alastair E. Moody, Charles E. Willyard, Nageshwara Gullapalli, Killian Boampong-Konam & Aaron T. Bowman. (2020) Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample. Thrombosis Research 194, pages 72-81.
Crossref
Crossref
Julia T. Fu, Evan Sholle, Spencer Krichevsky, Joseph Scandura & Thomas R. Campion. (2020) Extracting and classifying diagnosis dates from clinical notes: A case study. Journal of Biomedical Informatics 110, pages 103569.
Crossref
Crossref
Norio Komatsu, GyungJin Jun, Toshio Yonezu & Yasuo Ohashi. (2020) Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. International Journal of Hematology 112:2, pages 176-184.
Crossref
Crossref
Jennifer Huberty, Ryan Eckert, Linda Larkey, Jonathan Kurka, Sue A Rodríguez De Jesús, Wonsuk Yoo & Ruben Mesa. (2019) Smartphone-Based Meditation for Myeloproliferative Neoplasm Patients: Feasibility Study to Inform Future Trials. JMIR Formative Research 3:2, pages e12662.
Crossref
Crossref
Shreekant V. ParasuramanNianwen ShiDilan C. ParanagamaMachaon Bonafede. (2018) Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. Journal of Managed Care & Specialty Pharmacy 24:1, pages 47-55.
Crossref
Crossref
María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz & Rudi Subirá. (2017) Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Journal of Health Economics and Outcomes Research 5:2, pages 162-174.
Crossref
Crossref
Justyna Bartoszko, Tony Panzarella, Caroline Jane McNamara, Anthea Lau, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Dawn Maze, Karen W.L. Yee, Rebecca Devlin & Vikas Gupta. (2017) Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. Clinical Lymphoma Myeloma and Leukemia 17:11, pages 774-781.
Crossref
Crossref
M Marchetti, G Barosi, F Cervantes, G Birgegård, M Griesshammer, C Harrison, R Hehlmann, J-J Kiladjian, N Kröger, M F McMullin, F Passamonti, A Vannucchi & T Barbui. (2016) Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia 31:4, pages 882-888.
Crossref
Crossref
Ja Min Byun, Young Jin Kim, Taemi Youk, John Jeongseok Yang, Jongha Yoo & Tae Sung Park. (2016) Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. Annals of Hematology 96:3, pages 373-381.
Crossref
Crossref
Yoojoo Lim, Jeong-Ok Lee & Soo-Mee Bang. (2016) Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. Journal of Korean Medical Science 31:10, pages 1579.
Crossref
Crossref
Michael H. Kroll, Laura C. Michaelis & Srdan Verstovsek. (2015) Mechanisms of thrombogenesis in polycythemia vera. Blood Reviews 29:4, pages 215-221.
Crossref
Crossref
Brady L. Stein, Alison R. Moliterno & Ramón V. Tiu. (2014) Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Annals of Hematology 93:12, pages 1965-1976.
Crossref
Crossref